Collegium Pharmaceutical, Inc. (COLL)

From the record

Collegium Pharmaceutical, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Collegium Pharmaceutical, Inc.'s 10 filed years say what it did: revenue went from $2 million in fiscal 2016 to $781 million in fiscal 2025, up 97.5% a year; it rose in 8 of 9 years; the deepest fall was 11% from fiscal 2020 to fiscal 2021; net income was positive in 5 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Collegium Pharmaceutical, Inc.'s diluted share count grew about 5.5% a year, and dividends and buybacks returned about 20% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 14 sales (8 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Collegium Pharmaceutical, Inc. earned about 21 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 28 cents per dollar of everything the company owns. Leverage: it owed about 82 cents per dollar of assets, and net share issuance: its share count shrank 1.8% over the year (the filed statements).

From the record

Collegium Pharmaceutical, Inc.'s standing among 315 graded names in its industry family: revenue of $781 million in fiscal 2025 ranks in the top 14% by size; a net margin of 8.1% ranks in the top 19%; revenue growth of 18.9% a year over the last 3 filed years ranks in the top 38% (its annual reports).

From the record

Collegium Pharmaceutical, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Karnani, Vikram (President and CEO, as filed), filing under that title since 2024-11-14, 2 years (bottom 23% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 5.5 years (bottom 47%); 10 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 22%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Collegium Pharmaceutical, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $231 million against no long-term debt tagged leaves 14% of its assets as net cash, bottom 32% of its family; cash from operations less capital spending is 42% of revenue (top 5%); a gross margin of 59.3% (bottom 37%) (its annual report).

From the record

Collegium Pharmaceutical, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 18.9% a year over the last three filed years against 97.5% over all 10, slowing (bottom 7% of its family); the newest year grew 23.6% (top 34%); capital spending grew 2.4% a year (top 36%) (its annual reports). Collegium Pharmaceutical, Inc. reported 6 product lines in fiscal 2025: Belbuca at $222 million (28%), Xtampza ER at $199 million (26%), Jornay Pm at $149 million (19%), and 3 more; 5 of 6 grew against the year before (its annual report).

From the record

Collegium Pharmaceutical, Inc.'s newest year against its own record: revenue of $781 million in fiscal 2025 came in 6% above the $737 million its prior three years' pace pointed to (top 36% of its family); net income of $63 million against a prior three-year average of $31 million (top 15%); a net margin of 8.1% against 4.7% before (bottom 41%) (its annual reports).